Enzalutamide Monotherapy

INDICATIONS FOR USE:

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Regimen Code</th>
<th>Reimbursement Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.</td>
<td>C61</td>
<td>00233a</td>
<td>CDS</td>
</tr>
<tr>
<td>Treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated</td>
<td>C61</td>
<td>00233b</td>
<td>CDS</td>
</tr>
<tr>
<td>The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC)</td>
<td>C61</td>
<td>00233c</td>
<td>Not approved</td>
</tr>
</tbody>
</table>

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Enzalutamide is administered as a single oral daily dose until disease progression or unacceptable toxicity develops.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enzalutamide</td>
<td>160mg daily</td>
<td>PO with or without food at the same time each day. Capsule should be swallowed whole with water.</td>
<td>Continuous</td>
</tr>
</tbody>
</table>

If a dose is missed at the usual time, the prescribed dose should be taken as close as possible to the usual time. If a patient misses a dose for a whole day, treatment should be resumed the following day with the usual daily dose.

Medical castration with an LHRH analogue should be continued during treatment of patients not surgically castrated.

ELIGIBILITY:

- Indications as above
- ECOG status
  - Metastatic CRPC: 0-2
  - Non-metastatic CRPC: 0-1

EXCLUSIONS:

- Hypersensitivity to enzalutamide or any of the excipients
- Severe hepatic impairment
- Uncontrolled hypertension
- Patients suffering from fructose intolerance
PREScriptive AUTHORITY:
The treatment plan must be initiated by a Consultant Medical Oncologist.

TESTS:

Baseline tests:
- FBC, renal and liver profile.
- Blood pressure, ECG in patients at risk of QT prolongation.
- INR for patients on warfarin.

Regular tests:
- 4 weekly FBC, U&Es, LFTs as clinically indicated
- ECG, creatinine as clinically indicated
- Weekly INR tests if patient is on warfarin until stable warfarin dose established

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:
- Any dose modification should be discussed with a Consultant.

Renal and Hepatic Impairment:

<table>
<thead>
<tr>
<th>Renal Impairment</th>
<th>Hepatic Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>No dose adjustment is necessary for patients with mild or moderate renal impairment. Caution is advised in patients with severe renal impairment or end-stage renal disease.</td>
<td>No dose modification is necessary for patients with mild, moderate or severe hepatic impairment (Child Pugh Class A, B or C respectively. An increased drug half-life has however been observed in patients with severe hepatic impairment.</td>
</tr>
</tbody>
</table>

Management of adverse events:

<table>
<thead>
<tr>
<th>Adverse reactions</th>
<th>Recommended dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intolerable or ≥ Grade 3</td>
<td>Interrupt therapy for 7 days or until symptoms resolved to ≤ grade 2, then treatment may be resumed at the same dose or a reduced dose (120mg or 80mg) if warranted.</td>
</tr>
<tr>
<td>Seizures</td>
<td>Discontinue</td>
</tr>
<tr>
<td>Severe hypertension</td>
<td>Interrupt therapy until hypertension has been controlled.</td>
</tr>
</tbody>
</table>

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician. and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer.

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens.
Concomitant use with strong CYP2C8 inhibitors:
- The concomitant use of strong CYP2C8 inhibitors should be avoided if possible.
- If patients must be co-administered a strong CYP2C8 inhibitor, the dose of enzalutamide should be reduced to 80mg once daily.
- If co-administration of the strong CYP2C8 inhibitor is discontinued, the enzalutamide dose should be returned to the dose used prior to initiation of the strong CYP2C8 inhibitors.

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL: Minimal (Refer to local policy).

PREMEDICATIONS: Not usually required

OTHER SUPPORTIVE CARE:
Enzalutamide may have a moderate influence on the ability to drive and use machines as psychiatric and neurologic events including seizures have been reported. Patients with a history of seizures or other predisposing factors should be advised of the risk of driving or operating machines.

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS:
The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Risk of seizure**: Enzalutamide is associated with an increased risk of seizure, with a greater risk of seizure at daily doses >160mg. Caution is advised in administering the drug to patients with a history of seizure or other predisposing factors.
- **Posterior reversible encephalopathy syndrome (PRES)**: There have been rare reports of PRES in patients receiving enzalutamide treatment. Discontinuation of enzalutamide in patients who develop PRES is recommended.
- **Concomitant use with other medicinal products**:
  - Enzalutamide is a potent enzyme inducer and may lead to loss of efficacy of many commonly used medicinal products. A review of concomitant medicinal products should therefore be conducted when initiating enzalutamide treatment.
  - Concomitant use of enzalutamide with medicinal products that are sensitive substrates of many metabolising enzymes or transporters should generally be avoided if their therapeutic effect is of large importance to the patient, and if dose adjustments cannot easily be performed based on monitoring of efficacy or plasma concentrations.
  - Enzymes that may be induced include CYP3A in the liver and gut, CYP2C9, CYP2C19, CYP1A2 and uridine 5'-diphospho-glucuronosyltransferase (UGTs - glucuronide conjugating enzymes). The transport protein P-gp may also be induced, and probably other transporters as well, e.g. multidrug resistance-associated protein 2 (MRP2), breast cancer resistant protein (BCRP) and the organic anion transporting polypeptide 1B1 (OATP1B1).
  - The full induction potential of enzalutamide may not occur until approximately 1 month after the start of treatment, when steady-state plasma concentrations of enzalutamide are reached, although some induction effects may be apparent earlier.
In consideration of the long half-life of enzalutamide (5.8 days), effects on enzymes may persist for one month or longer after stopping enzalutamide. A gradual dose reduction of the concomitant medicinal product may be necessary when stopping enzalutamide treatment.

**Cardiovascular disease:** Exercise caution in patients with significant cardiovascular disease, history of hypertension or QT prolongation, risk factors for torsades de pointes, or on medications known for QT prolongation. Androgen ablation therapy may prolong the QT interval. Enzalutamide is associated with increased blood pressure in approximately 7% of patients. Hypertension rarely leads to discontinuation or dose modification but may require antihypertensive treatment. Temporary suspension of enzalutamide is recommended in patients with severe hypertension (>200mmHg systolic or >110mgHg diastolic). Treatment with enzalutamide may be resumed once hypertension is controlled.

**DRUG INTERACTIONS:**

- CYP2C8 inhibitors and inducers affect plasma concentrations of enzalutamide and should be avoided or used with caution during enzalutamide treatment. If patients must be co-administered a strong CYP2C8 inhibitor, the dose of enzalutamide should be reduced to 80mg once daily.
- Current drug interaction databases should be consulted for more information.

**ATC CODE:**

Enzalutamide - L02BB03

**REFERENCES:**


---

**NCCP Regimen: Enzalutamide Monotherapy**

**Published:** 18/01/2016  
**Review:** 04/09/2021  
**Version number:** 5

**Tumour Group:** Genitourinary  
**NCCP Regimen Code:** 00233  
**ISMO Contributor:** Dr Miriam O’Connor, Dr Ray McDermott, Prof Maccon Keane

---

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician. and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer.

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens.
NCCP Chemotherapy Regimen

<table>
<thead>
<tr>
<th>NCCP Regimen: Enzalutamide Monotherapy</th>
<th>Published: 18/01/2016</th>
<th>Version number: 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumour Group: Genitourinary</td>
<td>ISMO Contributor: Dr Miriam O’Connor, Dr Ray McDermott, Prof Maccon Keane</td>
<td>Page 5 of 5</td>
</tr>
<tr>
<td>NCCP Regimen Code: 00233</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE’s terms of use available at [http://www.hse.ie/eng/Disclaimer](http://www.hse.ie/eng/Disclaimer).

This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens).

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

1 Post 2012 indication. Not reimbursed through the ODMS or Community Drug Schemes (including the High Tech arrangements of the PCRS community drug schemes). Please check [https://www.hse.ie/eng/services/list/5/cancer/proinfo/medonc/cdmp/new.html](https://www.hse.ie/eng/services/list/5/cancer/proinfo/medonc/cdmp/new.html) for the most up to date reimbursement approvals.

ODMS – Oncology Drug Management System
CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes

---

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Description</th>
<th>Contributor</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>20/06/2018</td>
<td>Updated with new NCCP regimen template Clarified dosing with concomitant use with strong CYP2C8 inhibitors</td>
<td>Prof Maccon Keane</td>
</tr>
<tr>
<td>5</td>
<td>04/09/2019</td>
<td>Inclusion of new indication</td>
<td>Prof Maccon Keane</td>
</tr>
</tbody>
</table>